Cannabinoids for Neurodegenerative Disorders

Name: Cannabinoids for Neurodegenerative Disorders
Uploaded: 2024-09-26 21:20:28
Description: Discover the latest research on how cannabinoids may help manage symptoms and positively impact quality of life and the progression of conditions like dementia and ALS. Clinical case reports are shared and dosing strategies are discussed in depth, covering how to start a patient on cannabinoids and how to create an effective cannabinoid-based regimen.

Education Webinars Cannabinoids for Neurodegenerative Disorders

Discover the latest research on how cannabinoids may help manage symptoms and positively impact quality of life and the progression of conditions like dementia and ALS. Clinical case reports are shared and dosing strategies are discussed in depth, covering how to start a patient on cannabinoids and how to create an effective cannabinoid-based regimen.

Integrate Powerful Hemp Cannabinoids into your Healthcare Practice

Learn from leading cannabis clinician Bonni Goldstein, MD and grow your practice revenues through our lab-tested hemp extract marketplace, while providing an exclusive medical discount to your patients. For a limited time, our platform is free for licensed US healthcare practitioners only.

With your free account, you'll get access to this educational video and so much more!

Learn more Create your free account

View Sources

Aguzzi, C., Zeppa, L., Morelli, M. B., Marinelli, O., Giangrossi, M., Amantini, C., … Nabissi, M. (2024). Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma. BioFactors, 50(6), 1208–1219.

Amada, N., Yamasaki, Y., Williams, C. M., & Whalley, B. J. (2013). Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ, 1, e214.

Anderson, B. D., Sepulveda, D. E., Nachnani, R., Cortez-Resendiz, A., Coates, M. D., Beckett, A., … Raup-Konsavage, W. M. (2024). High cannabigerol hemp extract moderates colitis and modulates the microbiome in an inflammatory bowel disease model. Journal of Pharmacology and Experimental Therapeutics, 390(3), 331–341.

Anderson, L. L., Low, I. K., Banister, S. D., McGregor, I. S., & Arnold, J. C. (2019). Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. Journal of Natural Products, 82(11), 3047–3055.

Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., … Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure–activity study. Journal of Natural Products, 71(8), 1427–1430.

Aso, E., Juvés, S., Maldonado, R., & Ferrer, I. (2012). CB2 agonist ameliorates Alzheimer-like phenotype. Journal of Alzheimer’s Disease, 30(2), 439–459.

Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., & Ferrer, I. (2013). Cannabinoids modulate Alzheimer’s pathology. Journal of Alzheimer’s Disease, 35(4), 847–858.

Aso, E., Andrés-Benito, P., & Ferrer, I. (2016). Delaying neurodegeneration with cannabinoids. Journal of Alzheimer’s Disease, 54(2), 683–698.

Behl, T., Madaan, P., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., … Bungau, S. (2020). Endocannabinoid signaling in Parkinson’s disease. Pharmacological Research, 152, 104545.

Bilkei-Gorzo, A. (2012). The endocannabinoid system in normal and pathological brain ageing. Philosophical Transactions of the Royal Society B, 367(1607), 3326–3341.

Bonn-Miller, M. O., et al. (2024). A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology, 32(3), 277.

Broers, B., Patà, Z., Mina, A., Wampfler, J., de Saussure, C., & Pautex, S. (2019). Prescription of a THC/CBD-based medication to patients with dementia. Medical Cannabis and Cannabinoids, 2(1), 56–63.

Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., … Wang, J. (2014). The potential therapeutic effects of THC on Alzheimer’s disease. Journal of Alzheimer’s Disease, 42(3), 973–984.

Carroll, C. B., Bain, P. G., Teare, L., et al. (2004). Cannabis for dyskinesia in Parkinson’s disease. Neurology, 63(7), 1245–1250.

Chagas, M. H. N., et al. (2014). Cannabidiol improves quality of life in Parkinson’s disease. Journal of Psychopharmacology, 28(11), 1088–1098.

Corroon, J. (2021). Cannabinol and sleep: Separating fact from fiction. Cannabis and Cannabinoid Research, 6(5), 366–371.

Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2006). Cannabidiol inhibits inflammatory pathways in Alzheimer’s disease. Journal of Neurochemistry, 98(1), 106–115.

Farrimond, J. A., Whalley, B. J., & Williams, C. M. (2012). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology, 223(1), 117–129.

Greenbaum, L., et al. (2012). Association of FAAH polymorphism with Parkinson’s disease. Movement Disorders, 27(10), 1356–1359.

Herrmann, N., Ruthirakuhan, M., Gallagher, D., et al. (2019). Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. American Journal of Geriatric Psychiatry, 27(11), 1161–1173.

Hill, A. J., Weston, S. E., Jones, N. A., Smith, I., Bevan, S. A., Williamson, E. M., & Stephens, G. J. (2012). Cannabidivarin is anticonvulsant in mice and rats. British Journal of Pharmacology, 167(8), 1629–1642.

Huizenga, M. N., Sepulveda-Rodriguez, A., & Forcelli, P. A. (2019). Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology, 148, 189–198.

Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., … Tan, G. D. (2016). Cannabidiol and THCV effects in type 2 diabetes. Diabetes Care, 39, 1–10.

Leelawat, S., et al. (2022). Antitumor effects of THC and CBN. Evidence-Based Complementary and Alternative Medicine, 2022, 6477132.

Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis use in Parkinson’s disease. Clinical Neuropharmacology, 37(2), 41–44.

Maione, S., Rossi, F., Guy, G., Stott, C., & Kikuchi, T. (2018). Cannabinoids for use in the treatment of neuropathic pain (U.S. Patent No. 9,895,342 B2). U.S. Patent and Trademark Office.

Morano, A., Cifelli, P., Nencini, P., Antonilli, L., Fattouch, J., Ruffolo, G., … Giallonardo, A. T. (2016). Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin. Epilepsia Open, 1(3–4), 145–151.

Piyanova, A., et al. (2015). Age-related changes in the endocannabinoid system in mice. Neurobiology of Aging, 36(9), 2738–2746.

Sagredo, O., et al. (2011). Cannabinoids and Huntington’s disease. British Journal of Pharmacology, 163(7), 1367–1379.

Shelef, A., Barak, Y., Berger, U., Paleacu, D., Tadger, S., Plopsky, I., & Baruch, Y. (2016). Safety and efficacy of medical cannabis oil for behavioral disturbances in dementia. Journal of Alzheimer’s Disease, 51(1), 15–19.

Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001). Cannabinoids reduce levodopa-induced dyskinesia. Neurology, 57(11), 2108–2111.

Urbi, B., et al. (2019). Cannabinoids in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 20(7–8), 511–518.

Valdeolivas, S., et al. (2017). Cannabinoids in Huntington’s disease models. Neuropharmacology, 114, 178–187.

Volicer, L., Stelly, M., Morris, J., McLaughlin, J., & Volicer, B. J. (1997). Effects of dronabinol in Alzheimer’s patients. International Journal of Geriatric Psychiatry, 12(9), 913–919.

Wang, L., Liu, J., Harvey-White, J., Zimmer, A., & Kunos, G. (2003). Endocannabinoid signaling in mice. Journal of Neuroscience, 23(4), 1394–1401.

Watt, G., et al. (2017). Cannabidiol in Alzheimer’s disease models.

Woodward, M. R., Harper, D. G., Stolyar, A., et al. (2014). Dronabinol for agitation in dementia. American Journal of Geriatric Psychiatry, 22(7), 707–715.

Yunusa, I., Alsumali, A., Garba, A. E., Regestein, Q. R., & Eguale, T. (2022). Atypical antipsychotics in dementia-related psychosis. JAMA Network Open, 5(3), e224029.

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., et al. (2009). Cannabidiol for psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23(8), 979–983.

Collapse